NASDAQ · SNDX
Healthcare · Biotechnology
$17.83
Down-$0.46 (-2.58%)
Updated Oct 6, 2026, 11:28 PM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SNDX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
SNDX closed at $17.83 after 20 trading sessions, down 10.58% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $17.58 | $17.98 | $17.57 | $17.83 | 1.46M |
| Oct 2, 2026 | $18.46 | $18.46 | $17.52 | $17.60 | 2.56M |
| Oct 1, 2026 | $18.56 | $18.869 | $18.05 | $18.22 | 1.43M |
| Sep 30, 2026 | $18.28 | $18.94 | $17.945 | $18.80 | 1.73M |
| Sep 29, 2026 | $17.895 | $18.31 | $17.75 | $18.235 | 1.5M |
| Sep 28, 2026 | $18.16 | $18.16 | $17.60 | $17.86 | 1.55M |
| Sep 25, 2026 | $18.03 | $18.3495 | $17.765 | $18.20 | 1.34M |
| Sep 24, 2026 | $17.52 | $18.11 | $17.18 | $17.97 | 2.07M |
| Sep 23, 2026 | $18.20 | $18.47 | $17.09 | $17.64 | 2.09M |
| Sep 22, 2026 | $18.23 | $18.56 | $17.97 | $18.185 | 1.67M |
| Sep 21, 2026 | $17.74 | $18.45 | $17.39 | $18.07 | 2.11M |
| Sep 18, 2026 | $17.645 | $17.95 | $17.37 | $17.62 | 5.18M |
| Sep 17, 2026 | $17.53 | $18.05 | $17.37 | $17.68 | 2.58M |
| Sep 16, 2026 | $18.08 | $18.11 | $17.25 | $17.28 | 2.33M |
| Sep 15, 2026 | $18.19 | $18.19 | $17.71 | $18.09 | 1.13M |
| Sep 14, 2026 | $18.30 | $18.68 | $18.235 | $18.35 | 1.19M |
| Sep 11, 2026 | $19.01 | $19.02 | $18.02 | $18.18 | 1.22M |
| Sep 10, 2026 | $19.67 | $19.69 | $18.40 | $18.82 | 1.65M |
| Sep 9, 2026 | $19.82 | $20.205 | $19.69 | $19.84 | 1.24M |
| Sep 8, 2026 | $20.19 | $20.48 | $19.90 | $19.94 | 1.21M |
The latest Smart Investors Daily articles mentioning SNDX.
Company
Market Activity
Research & News
SNDX research
Company profile and research snapshot.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 21, 2026 | UBS | Buy | — |
| Aug 11, 2026 | JP Morgan | Overweight | — |
| Aug 5, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 15, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 12, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 29, 2026
Note: The stock trades discussed in this article come from AI Finance Labs, an investment experiment that operates publicly viewable portfolios directed by models including Claude, ChatGPT, Grok and DeepSeek. Anthropic’s Claude AI recently sold its positions in Ardelyx Inc. (NASDAQ: ARDX) and Aris Mining Corp. (NYSE: ARIS) and replaced them with Syndax Pharmaceuticals Inc. […]
SeekingAlpha · Sep 28, 2026
Syndax achieved FDA approval for Revuforj in r/r mNPM1 AML and is pursuing pivotal studies to expand into 1st-line AML populations. Read why SNDX is a Strong Buy.
SeekingAlpha · Sep 25, 2026
Syndax Pharmaceuticals, Inc. growth outlook: Revuforj AML data boosts confidence, $2B+ peak sales target, pipeline catalysts ahead. Click for this SNDX update.
SeekingAlpha · Sep 10, 2026
Syndax Pharmaceuticals, Inc. (SNDX) Citigroup's Biopharma Back to School Summit 2026 September 10, 2026 8:40 AM EDTCompany ParticipantsMichael Metzger - CEO...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SNDX.
